DAFTAR PUSTAKA

Angele, MK. *et al.* (2014) ‘Gender differences in sepsis: Cardiovascular and immunological aspects’, *Virulence*, 5(1), pp. 12–9.

Angus, D. C. and Van der Poll, T. (2013) ‘Severe Sepsis and Septic Shock’, *New England Journal of Medicine*, 369(9), pp. 840–851.

Buonacera, A. *et al.* (2022) ‘Neutrophil to Lymphocyte Ratio: An Emerging Marker of the Relationships between the Immune System and Diseases’, *International Journal of Molecular Sciences*, 23(7), pp. 1–10.

Channappanavar, R. and Perlman, S. (2017) 'Pathogenic human infections: causes and consequences of cytokine storm and immunopathology', *Semin Immunopathol*, 39(5), pp. 529-539.

Depkes (2017) *Kepmenkes Nomor HK.01.07/MENKES/342/2017 tentang Pedoman Nasional Pelayanan Kedokteran Tatalaksana Sepsis*. Jakarta: Kementerian Kesehatan RI.

Doi, K. (2016) ‘Role of Kidney Injury in Sepsis’, *Journal of Intensive Care*, 4, pp. 1–6.

Drăgoescu, A. N. *et al.* (2022) ‘Neutrophil to Lymphocyte Ratio (NLR)—A Useful Tool for the Prognosis of Sepsis in the ICU’, *Biomedicines*, 10(1), p. 75.

Evans, L. *et al.* (2021) ‘Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021’, *Critical Care Medicine*, 49(11), pp. 1181–1247.

Evans, T. (2018) ‘Diagnosis and Management of Sepsis’, *Clinical Medicine*, 18(2), pp. 146–149.

Finkelsztein, E. J. *et al.* (2017) ‘Comparison of qSOFA and SIRS for Predicting Adverse Outcomes of Patients with Suspicion of Sepsis Outside The Intensive Care Unit’, *Critical Care*, 21(1), pp. 73–73.

Gotts, J. E. and Mathay, M. A. (2016) ‘Sepsis: Pathopysiology and Clinical Management’, *BMJ*, 353.

Grabe, M. *et al.* (2015) ‘Guidelines on Urological Infections’, *European Association of Urology*, 182, pp. 237–257.

Gunawan, I. S. (2021) *Rasio Neutrofil-Limfosit Sebagai Faktor Prediktor Kematian Pasien Sepsis di Pediatric Intensive Care Unit (PICU)*. Universitas Gadjah Mada Yogyakarta.

Hwang, SY. *et al.* (2017) 'Neutrophil-to-lymphocyte ratio as a prognostic marker in critically-ill septic patients', *Am J Emerg Med*, 2017;35(2):234–239.

Hermawan, A. G. (2016) *Buku Ajar Ilmu Penyakit Dalam, Sepsis*. 6th edn. Jakarta: Interna Publishing.

Jekarl, D. W. *et al.* (2019) ‘Procalcitonin As a Prognostic Marker for Sepsis based on Sepsis 3’, *Journal of Clinical Laboratory Analysis*, 33(9), pp. 1–7.

Karakonstantis, S. *et al.* (2018) ‘Pitfalls in Studies of Eosinopenia and Neutrophil-to-lymphocyte Count Ratio’, *Infectious Diseases*, 50(3), pp. 163–174.

LaRosa, D. F. and Orange, J. S. (2007) ‘1. Lymphocytes’, *Journal of Allergy and Clinical Immunology*, 121(2), pp. 364–369.

Li, Y. *et al.* (2019) ‘The Regulatory Roles of Neutrophils in Adaptive Immunity’, *Cell Communication and Signaling*, 17(1), pp. 1–11.

Liliriawati, A. K. (2023) *Hubungan Antara Polimorfisme Lokus rs7041, rs4588 Pada Gen Reseptor Protein Pengikat Vitamin D Dengan Mortalitas Pasien*

Sepsis. Universitas Andalas.

Liu, X. *et al.* (2016) 'Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Patients with Sepsis: A Prospective Observational Study', *Mediators of Inflammation*, 2016, p. 8191254.

Lowsby, R. *et al.* (2015) 'Neutrophil to Lymphocyte Count Ratio as an Early Indicator of Blood Stream Infection in the Emergency Department', *Emergency Medicine Journal*, 32(7), pp. 531–534.

Lubis, B. *et al.* (2021) 'Hubungan Neutrophil–Lymphocyte Ratio (NLR) Terhadap Mortalitas Pasien Sepsis di Unit Perawatan Intensif RSUP Haji Adam Malik Pada Tahun 2018', *Majalah Anestesia & Critical Care*, 39(1), pp. 12–18.

Maclay, T. and Rephann, A. (2017) 'The Impact of Early Identification and a Critical Care-Based Sepsis Response Team on Sepsis Outcomes', *Critical Care Nurse*, 37(6), pp. 88–91.

Maqbul, P. L., Leksana, E. and Harahap, M. S. (2016) 'Rasio Netrofil Limfosit dan Limfositopenia Sebagai Penanda Sepsis', *Medica Hospitalia: Journal of Clinical Medicine*, 6(1), pp. 54–58.

Menkes RI (2017) *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/342/2017 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Sepsis*. Jakarta: Menteri Kesehatan Republik Indonesia.

Mortaz, E. *et al.* (2018) 'Update on Neutrophil Function in Severe Inflammation', *Frontiers in Immunology*, 9, p. 2171.

Phua, J. *et al.* (2011) 'Management of Severe Sepsis in Patients Admitted to Asian Intensive Care Units: Prospective Cohort Study', *BMJ*, 342.

Rhodes, A. *et al.* (2017) 'Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock', *Intensive Care Medicine*, 43, pp. 304–377.

Salciccioli, J. D. *et al.* (2015) 'The Association Between The Neutrophil-to-lymphocyte Ratio and Mortality in Critical Illness: An Observational Cohort Study', *Critical Care*, 19(1), pp. 1–8.

Setiati, S. *et al.* (2016) *Buku Ajar Ilmu Penyakit Dalam*. Jakarta: Interna Publishing.

Seymour, C. W. and Angus, D. C. (2018) 'Sepsis and Septic Shock. In: Jameson J, Kasper D, Longo D, et al.', *Harrison's Principles of Internal Medicine*, pp. 2044–2052.

Siloşi, C. A. *et al.* (2018) 'Sepsis and Identification of Reliable Biomarkers for Postoperative Period Prognosis', *Rom Journal Morphol Embryol*, 59(1), pp. 77–91.

Singer, M. *et al.* (2016) 'The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)', *Jama*, 315(8), pp. 801–810.

Song, M. *et al.* (2021) 'Neutrophil-to-lymphocyte Ratio and Mortality in The United States General Population', *Scientific Reports*, 11(1), p. 464.

Tambajong, R. N., Lalenoh, D. C. and Kumaat, L. (2016) 'Profil Penderita Sepsis di ICU RSUP Prof. Dr. R. D. Kandou Manado Periode Desember 2014 – November 2015', *e-CliniC*, 15(2), p. 2.

Vakkalanka, J. P. *et al.* (2018) 'Clinical and Epidemiological Variability in Severe Sepsis: An Ecological Study', *Journal Epidemiol Community Health*, 72(8), pp. 741–745.

WHO (2020a) *Global Report on the Epidemiology and Burden of Sepsis: Current*

Evidence, Identifying Gaps and Future Directions. Geneva: World Health Organization.

WHO (2020b) *Newsroom Sepsis*. Available at: https://www.who.int/news-room/fact-sheets/detail/sepsis (Accessed: 19 September 2023).

LAMPIRAN

Lampiran 1. Master Tabel

No.	JK	Usia	No. RM	Neutrophil 1	Neutrophil 2	Lymphocyte 1	Lymphocyte 2	NLR 1	NLR 2	Prognosis	Keterangan
1	1	59	9891**	93.1	90.4	4.2	3.6	22.2	25.1	*Non-Survivor*	Meninggal
2	2	60	9998**	90.4	81.2	3.6	6.3	25.1	12.9	*Non-Survivor*	Meninggal
3	1	59	9982**	77.4	91.5	4.9	7	15.8	13.1	*Non-Survivor*	Meninggal
4	1	52	9648**	86.2	77.4	6.6	12.6	13.1	6.1	*Non-Survivor*	Meninggal
5	2	52	9978**	75	88	16.6	7.3	4.5	12.1	*Non-Survivor*	Meninggal
6	2	31	9855**	82.6	98.9	9.5	0.5	8.7	197.8	*Non-Survivor*	Meninggal
7	1	60	9854**	85	81	8.1	10.8	10.5	7.5	*Non-Survivor*	Meninggal
8	2	35	9994**	89.9	88.2	6	5	15.0	17.6	*Non-Survivor*	Meninggal
9	2	57	9945**	95.9	80.2	2.5	8	38.4	10.0	*Non-Survivor*	Meninggal
10	2	35	9861**	81.2	94.9	9	1.4	9.0	67.8	*Non-Survivor*	Meninggal
11	1	53	8278**	74.1	88.5	1	1.7	74.1	52.1	*Non-Survivor*	Meninggal
12	1	62	9905**	83.6	96.5	9	3	9.3	32.2	*Non-Survivor*	Meninggal
13	2	59	9711**	74.9	97.7	12	0.9	6.2	108.6	*Non-Survivor*	Meninggal
14	1	20	9845**	86.4	69.1	5.9	22.6	14.6	3.1	*Non-Survivor*	Meninggal
15	1	64	9858**	76.6	82.8	12.2	5.2	6.3	15.9	*Non-Survivor*	Meninggal
16	1	44	9921**	86.6	69.5	6.7	13.1	12.9	5.3	*Non-Survivor*	Meninggal
17	1	47	9685**	92.6	77.7	2.3	10.4	40.3	7.5	*Non-Survivor*	Meninggal
18	2	56	9718**	95	88.2	2.9	4.5	32.8	19.6	*Non-Survivor*	Meninggal
19	2	54	9858**	77.2	73.7	14.8	16.5	5.2	4.5	*Non-Survivor*	Meninggal
20	1	48	10007**	83.1	90.9	8.3	6.6	10.0	13.8	*Non-Survivor*	Meninggal
21	1	21	9939**	90.9	85.2	6.6	5.7	13.8	14.9	*Non-Survivor*	Meninggal
22	2	34	9693**	91.8	79.9	2.8	5.2	32.8	15.4	*Non-Survivor*	Meninggal
23	2	31	9875**	69.3	82	16.4	11.4	4.2	7.2	*Non-Survivor*	Meninggal
24	1	55	9796**	80.7	95.4	4.1	1.4	19.7	68.1	*Non-Survivor*	Meninggal
25	1	38	9934**	80.5	68	10.4	20.4	7.7	3.3	*Non-Survivor*	Meninggal
26	1	53	9721**	74	90.5	13.5	4.2	5.5	21.5	*Non-Survivor*	Meninggal
27	2	37	9311**	90.1	85.8	6.4	8.3	14.1	10.3	*Non-Survivor*	Meninggal
28	1	54	5190**	90.3	95.5	3.6	1.4	25.1	68.2	*Non-Survivor*	Meninggal
29	2	32	9557**	88	93.7	6.1	3	14.4	31.2	*Non-Survivor*	Meninggal

30	2	27	9955**	81.7	79.7	12	7.2	6.8	11.1	*Non-Survivor*	Meninggal
31	2	52	9614**	75.4	65.4	16.5	21.4	4.6	3.1	*Non-Survivor*	Meninggal
32	1	53	9979**	76.6	94	7.9	4.5	9.7	20.9	*Non-Survivor*	Meninggal
33	2	30	4322**	89.9	87.7	6.5	6.1	13.8	14.4	*Non-Survivor*	Meninggal
34	2	45	8844**	87.4	67.4	7.2	24.9	12.1	2.7	*Non-Survivor*	Meninggal
35	2	47	9993**	95.1	97.6	2.6	1	36.6	97.6	*Non-Survivor*	Meninggal
36	2	53	9549**	80.1	73.2	11.2	5.1	7.2	14.4	*Non-Survivor*	Meninggal
37	2	79	9704**	80.1	82.8	12.2	5.2	6.6	15.9	*Non-Survivor*	Meninggal
38	2	76	9841**	89.4	81.2	3.6	5.9	24.8	13.8	*Non-Survivor*	Meninggal
39	1	71	9994**	75.3	83.4	11.4	4.1	6.6	20.3	*Non-Survivor*	Meninggal
40	1	72	9946**	84.5	95.4	9.2	4	9.2	23.9	*Non-Survivor*	Meninggal
41	2	79	4314**	74	97.7	11.6	9.2	6.4	10.6	*Non-Survivor*	Meninggal
42	1	73	9784**	75.4	89.9	9	3.4	8.4	26.4	*Non-Survivor*	Meninggal
43	1	66	9909**	78.1	91.2	9.9	7.6	7.9	12.0	*Non-Survivor*	Meninggal
44	1	70	9903**	84	92	13.4	7.9	6.3	11.6	*Non-Survivor*	Meninggal
45	1	30	1072**	93.3	57.2	2.3	32.6	40.6	1.8	*Survivor*	Membaik
46	1	41	9967**	85.3	79.3	6.8	9.9	12.5	8.0	*Survivor*	Membaik
47	1	37	9764**	90.7	75.5	5.6	13.2	16.2	5.7	*Survivor*	Membaik
48	1	62	9824**	78.2	73.2	8	11.6	9.8	6.3	*Survivor*	Membaik
49	2	32	9849**	89.8	90.5	5	12.9	18.0	7.0	*Survivor*	Membaik
50	1	53	383**	91.1	62.6	6.4	22.8	14.2	2.7	*Survivor*	Membaik
51	1	59	5097**	87.4	74	6.3	16.4	13.9	4.5	*Survivor*	Membaik
52	1	27	9801**	65.5	47.5	4.7	31.2	13.9	1.5	*Survivor*	Membaik
53	1	49	1000**	82.6	72.3	9.5	14	8.7	5.2	*Survivor*	Membaik
54	1	54	9905**	86.2	84.6	9.8	9.5	8.8	8.9	*Survivor*	Membaik
55	1	42	9780**	74.5	67.1	10.9	15.7	6.8	4.3	*Survivor*	Membaik
56	2	56	9868**	92.5	63.6	3.6	18.4	25.7	3.5	*Survivor*	Membaik
57	1	62	9639**	86.4	59.7	11.4	32.7	7.6	1.8	*Survivor*	Membaik
58	1	41	9148**	88.9	77	6.7	14.6	13.3	5.3	*Survivor*	Membaik

Lampiran 2. Pengolahan Data

T-Test

Group Statistics

	Prognosis	N	Mean	Std. Deviation	Std. Error Mean
Neutrofil awal	Non-Survivor	44	83,3955	6,99342	1,05430
	Survivor	14	85,1714	7,76793	2,07607
Neutrofil akhir	Non-Survivor	44	85,4750	9,24220	1,39331
	Survivor	14	70,2929	11,46832	3,06504
Limfosit awal	Non-Survivor	44	8,19	4,186	0,631
	Survivor	14	6,93	2,710	0,724
Limfosit akhir	Non-Survivor	44	7,3977	5,92655	0,89346
	Survivor	14	18,2500	8,26994	2,21023
NLR awal	Non-Survivor	44	15,4159	13,31558	2,00740
	Survivor	14	15,0000	8,85638	2,36697
NLR akhir	Non-Survivor	44	26,6227	35,77210	5,39285
	Survivor	14	4,7500	2,33131	0,62307

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means	
		F	Sig.	t	df
Neutrofil awal	Equal variances assumed	0,052	0,820	-0,806	56
	Equal variances not assumed			-0,763	20,164
Neutrofil akhir	Equal variances assumed	0,806	0,373	5,047	56
	Equal variances not assumed			4,509	18,687
Limfosit awal	Equal variances assumed	4,065	0,049	1,053	56
	Equal variances not assumed			1,309	34,262
Limfosit akhir	Equal variances assumed	3,380	0,071	-5,403	56
	Equal variances not assumed			-4,552	17,455
NLR awal	Equal variances assumed	1,575	0,215	0,109	56
	Equal variances not assumed			0,134	33,229
NLR akhir	Equal variances assumed	7,135	0,010	2,273	56
	Equal variances not assumed			4,029	44,130

Independent Samples Test

		t-test for Equality of Means		
		Sig. (2-tailed)	Mean Difference	Std. Error Difference
Neutrofil awal	Equal variances assumed	0,424	-1,77597	2,20337
	Equal variances not assumed	0,454	-1,77597	2,32843
Neutrofil akhir	Equal variances assumed	0,000	15,18214	3,00838
	Equal variances not assumed	0,000	15,18214	3,36686
Limfosit awal	Equal variances assumed	0,297	1,258	1,195
	Equal variances not assumed	0,199	1,258	0,961
Limfosit akhir	Equal variances assumed	0,000	-10,85227	2,00855
	Equal variances not assumed	0,000	-10,85227	2,38399
NLR awal	Equal variances assumed	0,914	0,41591	3,81225
	Equal variances not assumed	0,894	0,41591	3,10358
NLR akhir	Equal variances assumed	0,027	21,87273	9,62469
	Equal variances not assumed	0,000	21,87273	5,42872

Independent Samples Test

		t-test for Equality of Means	
		95% Confidence Interval of the Difference	
		Lower	Upper
Neutrofil awal	Equal variances assumed	-6,18986	2,63791
	Equal variances not assumed	-6,63046	3,07851
Neutrofil akhir	Equal variances assumed	9,15563	21,20865
	Equal variances not assumed	8,12721	22,23707
Limfosit awal	Equal variances assumed	-1,136	3,651
	Equal variances not assumed	-0,694	3,209
Limfosit akhir	Equal variances assumed	-14,87589	-6,82866
	Equal variances not assumed	-15,87209	-5,83246
NLR awal	Equal variances assumed	-7,22094	8,05276
	Equal variances not assumed	-5,89671	6,72853
NLR akhir	Equal variances assumed	2,59215	41,15331
	Equal variances not assumed	10,93277	32,81269

Oneway

Descriptives

		N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean Lower Bound
Neutrofil awal	Non-Survivor	44	83,3955	6,99342	1,05430	81,2693
	Survivor	14	85,1714	7,76793	2,07607	80,6864
	Total	58	83,8241	7,15856	0,93997	81,9419
Neutrofil akhir	Non-Survivor	44	85,4750	9,24220	1,39331	82,6651
	Survivor	14	70,2929	11,46832	3,06504	63,6712
	Total	58	81,8103	11,72104	1,53905	78,7285
Limfosit awal	Non-Survivor	44	8,19	4,186	0,631	6,91
	Survivor	14	6,93	2,710	0,724	5,36
	Total	58	7,88	3,897	0,512	6,86
Limfosit akhir	Non-Survivor	44	7,3977	5,92655	0,89346	5,5959
	Survivor	14	18,2500	8,26994	2,21023	13,4751
	Total	58	10,0172	8,00246	1,05077	7,9131
NLR awal	Non-Survivor	44	15,4159	13,31558	2,00740	11,3676
	Survivor	14	15,0000	8,85638	2,36697	9,8865
	Total	58	15,3155	12,31573	1,61713	12,0773
NLR akhir	Non-Survivor	44	26,6227	35,77210	5,39285	15,7470
	Survivor	14	4,7500	2,33131	0,62307	3,4039
	Total	58	21,3431	32,49195	4,26640	12,7998

Descriptives

		95% Confidence Interval for Mean Upper Bound	Minimum	Maximum
Neutrofil awal	Non-Survivor	85,5216	69,30	95,90
	Survivor	89,6565	65,50	93,30
	Total	85,7064	65,50	95,90
Neutrofil akhir	Non-Survivor	88,2849	65,40	98,90
	Survivor	76,9145	47,50	90,50
	Total	84,8922	47,50	98,90
Limfosit awal	Non-Survivor	9,46	1	17
	Survivor	8,49	2	11
	Total	8,91	1	17
Limfosit akhir	Non-Survivor	9,1996	0,50	24,90
	Survivor	23,0249	9,50	32,70
	Total	12,1214	0,50	32,70
NLR awal	Non-Survivor	19,4642	4,20	74,10

	Survivor	20,1135	6,80	40,60
	Total	18,5538	4,20	74,10
NLR akhir	Non-Survivor	37,4984	2,70	197,80
	Survivor	6,0961	1,50	8,90
	Total	29,8864	1,50	197,80

ANOVA

		Sum of Squares	df	Mean Square	F	Sig.
Neutrofil awal	Between Groups	33,499	1	33,499	0,650	0,424
	Within Groups	2887,468	56	51,562		
	Total	2920,966	57			
Neutrofil akhir	Between Groups	2448,042	1	2448,042	25,468	0,000
	Within Groups	5382,772	56	96,121		
	Total	7830,814	57			
Limfosit awal	Between Groups	16,802	1	16,802	1,108	0,297
	Within Groups	848,940	56	15,160		
	Total	865,743	57			
Limfosit akhir	Between Groups	1250,818	1	1250,818	29,193	0,000
	Within Groups	2399,425	56	42,847		
	Total	3650,243	57			
NLR awal	Between Groups	1,837	1	1,837	0,012	0,914
	Within Groups	8643,759	56	154,353		
	Total	8645,596	57			
NLR akhir	Between Groups	5081,110	1	5081,110	5,165	0,027
	Within Groups	55095,312	56	983,845		
	Total	60176,422	57			